A practical reference on GLP-1 receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-05 and is reviewed periodically as new material appears.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
and related express business assets, and established SX Freight, an independent franchise model LTL freight company. In the same year, the company acquired Deutsche Post DHL Group and its supply chain business in mainland China, Hong Kong and Macau for RMB 5.5 billion. This includes DHL Global Forwarding (Hong Kong) LTD., Ocean Overseas Holdings Limited, and Deutsche Post Beteiligungen Holding GmbH. On February 18, 2019, it was officially renamed SF DHL Supply Chain China. In 2021, SF REIT was listed on the Main Board of the Hong Kong Stock Exchange. In the same year, SF Holding announced that it would spend RMB 17.56 billion to acquire a 51.8% stake in Kerry Logistics. After the completion of the process, SF Chairman Wang Wei was appointed as chairman of the board and Non-Executive Director of Kerry Logistics Network Limited. SF Holding also completed a private placement of A shares, raising a total of RMB 20 billion. In December 2021, SF Intra-city completed its listing on the Main Board of the Hong Kong Stock Exchange. In 2023, SF Holding was shortlisted for the Fortune Global 500. In the same year, it was shortlisted for the top 50 private logistics companies in China as evaluated by the China Federation of Logistics & Purchasing. The Ezhou cargo hub became China's first dedicated air cargo hub. The airport launched 48 domestic cargo routes and 17 international cargo routes, covering Asia and extending to Europe and America, forming an extensive air cargo network.
The mental capabilities of Minds are described in Excession to be vast enough to run entire universe-simulations inside their own imaginations, exploring metamathical (a fictional branch of metamathematics) scenarios, an activity addictive enough to cause some Minds to totally withdraw from caring about our own physical reality into "Infinite Fun Space", their own, ironic and understated term for this sort of activity.
== Ecology == A giant orchid weighing two tons was one of the highlights in the 1851 exhibition at the Crystal Palace in London. Because of its enormous size, it is rarely cultivated as this species is usually too large to be accommodated in most greenhouses. Cultivated specimens of this species are always grown as terrestrials, as the plants grow as both an epiphyte and terrestrial in habitat.
== Longevity and Healthspan Human Trial == Ho launched DELTA, a N=1 trial where Ho is the test subject. Approved by an institutional review board (IRB), DELTA is a prospective, interventional study that is exploring the use of digital health to optimise metabolic performance, sleep, gut health, and other aspects of healthspan. Early results from this study were published in a peer-reviewed article in PNAS Nexus. . Ho has spoken at international longevity, AI, and healthspan conferences on the DELTA trial and the impact of N=1 Health on population healthspan optimization.
Jainism teaches vegetarianism as moral conduct, as do some sects of Hinduism. Buddhism in general does not prohibit meat eating, but Mahayana Buddhism encourages vegetarianism as beneficial for developing compassion. Other denominations that advocate a vegetarian diet include the Seventh-day Adventists, the Rastafari movement, the Ananda Marga movement and the Hare Krishnas. Sikhism does not equate spirituality with diet and does not specify a vegetarian or meat diet.
Sources: en.wikipedia.org
=== Racial discrimination allegation (2011) === In 2011, a former employee filed a racial discrimination lawsuit alleging that he was fired after repeatedly having a Black man work the cash register instead of putting him in a less visible location, and assigning "pretty young girls" as the cashiers, as requested by supervisors. The plaintiff also said he was fired after requesting another month off after returning from three months of sick leave. Panera said that it "does not discriminate based on national origin, race or sex" and that the plaintiff "was terminated because he had used all of his medical leave and was unable to return to work". The plaintiff worked in a store owned by franchisee Sam Covelli, who also owns the stores that were involved in the 2003 racial discrimination lawsuit. Covelli Enterprises is the single largest franchisee of Panera Bread with nearly 300 stores in Ohio, Pennsylvania, West Virginia, and Florida. The lawsuit was settled in June 2012.
== Toxicodynamics == Apamin is the smallest neurotoxin polypeptide known, and the only one that passes the blood-brain barrier. Apamin thus reaches its target organ, the central nervous system. Here it inhibits small-conductance Ca2+-activated K+ channels (SK channels) in neurons. These channels are responsible for the afterhyperpolarizations that follow action potentials, and therefore regulate the repetitive firing frequency. Three different types of SK channels show different characteristics. Only SK2 and SK3 are blocked by apamin, whereas SK1 is apamin insensitive. SK channels function as a tetramer of subunits. Heteromers have intermediate sensitivity. SK channels are activated by the binding of intracellular Ca2+ to the protein calmodulin, which is constitutively associated to the channel. Transport of potassium ions out of the cell along their concentration gradient causes the membrane potential to become more negative. The SK channels are present in a wide range of excitable and non-excitable cells, including cells in the central nervous system, intestinal myocytes, endothelial cells, and hepatocytes. Binding of apamin to SK channels is mediated by amino acids in the pore region as well as extracellular amino acids of the SK channel. It is likely that the inhibition of SK channels is caused by blocking of the pore region, which hinders the transport of potassium ions. This will increase the neuronal excitability and lower the threshold for generating an action potential. Other toxins that block SK channels are tamapin and scyllatoxin.
Hydrogen cyanide is a bulk chemical; global production in 2001 was approximately 2.6 million tons. Key derivatives produced from it include adiponitrile, acetone cyanohydrin, sodium cyanide, and cyanuric chloride. Chelating agents are also synthesized from hydrogen cyanide, for example ethylenediaminetetraacetic acid from formaldehyde, ethylenediamine, hydrogen cyanide, and sodium hydroxide. An important industrial route to amino acids is the Strecker synthesis, in which hydrogen cyanide serves as a starting material. A quantitatively important amino acid is methionine, which is produced from acrolein, hydrogen cyanide, and hydrogen sulphide and is used primarily in animal feed.
The international nature of the high seas, means they have limited policing capabilities, which makes the oceans particularly vulnerable to the illicit drug trade. Excluding the 12 - 24 nautical miles surrounding each of the littoral states, the oceans are generally not owned by any particular country. Except for in their territorial waters, law enforcement ships can do very little in terms of policing unless a vessel is registered to their own country. These problems are heightened by a lack of international agreement and cooperation, resulting in an absence of sufficient legal infrastructure to handle the problem. This problem has been overcome previously, as laws have been implemented to enable the boarding of ships in relation to other maritime crimes, such as piracy, but this has not yet been effectively implemented in regards to drug trafficking. In practice, this has meant that vessels suspected of trafficking these illegal substances cannot be boarded by law enforcement, and thus face no legal consequences. Traffickers have taken advantage of this, and are increasingly capitalising on illicit trade through maritime routes. Of the 400 million containers shipped worldwide in 2009, only 2% of these were inspected.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。